A new oral therapy, TP-05, could transform Lyme disease prevention by targeting ticks before transmission, offering a flexible, on-demand option beyond traditional behavioral strategies in high-risk populations.
Roxana Francisco, MD, PhD
Advertisement
Roxana Francisco, MD, PhD, is the senior director of clinical development for Tarsus Pharmaceuticals.
Articles by Roxana Francisco, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Infection Control Today
1
AORN 2026 New Orleans: “Up in Smoke” Poster Urges Nationwide Surgical Smoke Evacuation Policy to Protect OR Staff and Patients
2
AORN 2026 New Orleans: Evidence-Based Colorectal SSI Bundle Reduces Surgical Infections Through Standardized Intraoperative Nursing Care
3
Emerging Oral Lyme Disease Prevention Strategy and TP-05’s Potential Impact on Public Health
4
AORN26: Teach-Back Method in PACU Discharge Education Reduces Surgical Site Infections
5